Wedbush lowered the firm’s price target on Werewolf Therapeutics (HOWL) to $6 from $8 to adjust future financing expectations following the recent price decline, while keeping an Outperform rating on the shares following quarterly results and updates regarding PREDATOR-masked products. WTX-124 remains on track to report initial clinical data in the second half of 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOWL:
- Werewolf Therapeutics Reports Q1 2025 Financial Results
- Werewolf Therapeutics files $150M mixed securities shelf
- Werewolf Therapeutics reports Q1 EPS (40c), consensus (43c)
- Werewolf Therapeutics Announces Q1 2025 Financial Results
- Werewolf Therapeutics presents new preclinical data on IL-10 INDUKINE